Sepracor, Inc.'s Phase III Arformoterol Study Data Presented At European Respiratory Society Annual Congress

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sept. 5, 2006--Sepracor Inc. (Nasdaq: SEPR) today announced that it presented a poster of pooled data from Phase III trials of arformoterol tartrate inhalation solution at the 16th Annual Congress of the European Respiratory Society (ERS) in Munich, Germany.

Back to news